Development of the COVID-19 vaccine

Development of the COVID-19 vaccine

immu II kt

immu II kt

Type I hypersensitivity
Type II hypersensitivity
Type III hypersensitivity
Type IV hypersensitivity
Food allergy
Anaphylaxis
Allergic rhinitis
Severe combined immunodeficiency
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
X-linked agammaglobulinemia
Selective immunoglobulin A deficiency
Common variable immunodeficiency
DiGeorge syndrome
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
Adenosine deaminase deficiency
Wiskott-Aldrich syndrome
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review
Complement deficiency
Leukocyte adhesion deficiency
Chronic granulomatous disease
Hashimoto thyroiditis
Graves disease
Myasthenia gravis
Diabetes mellitus
Goodpasture syndrome
Pemphigus vulgaris
Multiple sclerosis
Autoimmune hemolytic anemia
Immune thrombocytopenia
Primary biliary cholangitis
Celiac disease
Inflammatory bowel disease: Pathology review
Crohn disease
Ulcerative colitis
Sjogren syndrome
Rheumatoid arthritis
Dermatomyositis
Scleroderma
Systemic lupus erythematosus
Vaccinations: Clinical
Graft-versus-host disease
Ataxia-telangiectasia
HIV (AIDS)
HIV and AIDS: Pathology review
Immunodeficiencies: Clinical
Hyper IgM syndrome
COVID-19 vaccine hesitancy
Development of the COVID-19 vaccine
COVID-19 mutant variants and herd immunity
Imaging features of COVID-19 (LifeBridge Health)
Post-COVID syndrome: Mental health
Safety of the COVID-19 vaccines
Standards of care for COVID-19 patients
COVID-19 vaccines: What healthcare providers need to know
Post-COVID syndrome: Heart, lungs and clotting

Transcript

Watch video only

It seems like the whole world is holding its breath for the COVID19 vaccine.

But you might be wondering, how do we even go about making the COVID19 vaccine?

There are two main goals in vaccine development: First, the vaccine needs to be safe to administer to the general population.

Second, the vaccine needs to be efficacious against the pathogen, for instance a virus.

There are a couple ways to identify that - by seeing if it produces a significant immune response to the virus or by seeing if it reduces the chance of getting the disease itself.

Before a candidate vaccine even begins being administered to humans, it goes through extensive animal testing, typically using lab mice.

In this phase researchers are looking for side effects within the mice, which can range from mild skin irritation at the site of injection, to death.

Researchers also take blood samples from the mice over the next several days to weeks.

Researchers measure the blood antibody levels of the mice, and specifically look for antibodies being produced that would combat the virus.

A sufficient number of antibodies being produced after the vaccine is administered is a promising result.

Sometimes mice are given the virus to see if having the vaccine prevents them from getting the disease.

If there are no significant negative side effects and there’s evidence of vaccine efficacy, the vaccine can move to clinical trials.

Clinical trials are broken down in three phases, and are designed to measure both the safety of the candidate vaccine and the immune response, just like in mice.

In all of these phases, humans are given the candidate vaccine, and others are given a placebo with the goal to help make it easier to compare the efficaciousness of the vaccine.

Healthy adults are usually chosen for these studies because the goal is to ensure that they are least likely to develop a serious problem from the vaccine and so that if they do develop a health issue, it’s most likely from the vaccine and not from an underlying condition.